- R3918-MG
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Symptomatic Generalized Myasthenia Gravis
If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com
- Librexia
A Phase 3, Randomized, Double-Blind, Parallel-Group, Pacebo-controlled study to determine the efficacy and safety of Milvexian, an Oral Factor Xia Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
- Roche
Phase III, randomized, placebo controlled study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo as add-on therapy to standard of care for the treatment of gMG.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
- Alexion
Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of ALXN1720 in adults with generalized Myasthenia Gravis.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
- UCB
Phase IIIB, multicenter, open-label, single-arm study to evaluate the safety, tolerability, and efficacy of Zilucoplan in participants with generalized Myasthenia Gravis switching from intravenous complement component 5 inhibitors to subcutaneous Zilucoplan.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
- IMVT
This is a multi-center, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab in adult participants with active CIDP. The study includes a 4-week Screening Phase, an up to 12-week Washout Phase, a 12-week Randomized Treatment Phase (Period 1), an up to 24-week Randomized Withdrawal Phase (Period 2), a 4-week Safety follow-up for participants not entering Long-Term Extension (LTE), and a 52-week LTE Phase. The total study duration will be up to 104 weeks. Eligible participants will be assigned to one of three cohorts (A, B, C) based upon their CIDP treatment at the time of screening.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
- Oceanic
Phase 3 study to investigate the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) compared with placebo in participants after an acute non-cardioembolic ischemic stroke or high-risk TIA.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com